Track VolitionRx Limited — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

VolitionRx Limited VNRX · Stock Open VolitionRx Limited in new tab

0.2167 USD
EPS
-3.80
P/B
-0.07
Beta
1.16
Target Price
13.62 USD
Loading chart...
Key Metrics
Earnings dateMarch 30, 2027
EPS-3.80
Book Value-2.67
Price to Book-0.07
% Insiders3.322%
Growth
Revenue Growth-0.02%
Estimates
Forward P/E-0.22
Forward EPS-0.85
Target Mean Price13.62

DCF valuation

Model fair value for VolitionRx Limited (VNRX)
Result
Sign in to run the valuation for VNRX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
5 analysts · consensus None · mean target 13.62 USD (low 2.00, high 24.00) · as of 10 Nov 2026
Low 2.00
Mean 13.62
High 24.00
Price 0.2167
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

VolitionRx Limited Logo VolitionRx Limited Analysis (VNRX)

United States Health Care Official Website Stock

Is VolitionRx Limited a good investment? VolitionRx Limited (VNRX) is currently trading at 0.2167 USD. Market analysts have a consensus price target of 13.62 USD. This suggests a potential upside from current levels.

Earnings Schedule: VolitionRx Limited is expected to release its next earnings report on March 30, 2027. The market consensus estimate for Forward EPS is -0.85.

Investor FAQ

Does VolitionRx Limited pay a dividend?

No, it does not currently pay a dividend.

What asset class is VolitionRx Limited?

VolitionRx Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 30, 2027. The company currently has a trailing EPS of -3.80.

Company Profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Exchange Ticker
ASE (United States) VNRX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 28, 2026 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion